Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (957)

« Back to Publications

Myasthenic syndromes: mistaking genetic for acquired

Henehan L. et al, (2026), Practical Neurology, 26, 164 - 168

Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.

Yeh WZ. et al, (2026), J Neurol, 273

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica

Salih H. et al, (2026), Annals of Clinical and Translational Neurology, 13, 581 - 592

Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder

Greco G. et al, (2026), Multiple Sclerosis Journal, 32, 326 - 337

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Ramdas S. et al, (2026), Brain

Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis

John NA. et al, (2026), European Journal of Neurology, 33

EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

Young CA. et al, (2026), Value in Health, 29, 303 - 310

Prevalence and Geographical Distribution of Patients With Congenital Myasthenic Syndromes in the United Kingdom

Rossini E. et al, (2026), Muscle & Nerve, 73, 79 - 85

Plasma N -Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD, and MOGAD

Kacerova T. et al, (2025), Neurology Neuroimmunology & Neuroinflammation, 12

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study

Bennett JL. et al, (2025), Neurology Neuroimmunology & Neuroinflammation, 12

ECTRIMS 2024 Lecture: Unraveling the spectrum of the antibody-mediated demyelinating diseases: Emerging insights

Fadda G. and Palace J., (2025), Multiple Sclerosis Journal, 31, 1282 - 1293

Corrigendum to A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: the SCREAM study Lancet Reg Health West Pac (2023) 38: 100846

Li Z. et al, (2025), The Lancet Regional Health - Western Pacific, 63, 101665 - 101665

Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody–Associated Disease

Cortese R. et al, (2025), Neurology, 105

Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

Thakolwiboon S. et al, (2025), Neurology, 105

Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study

Bennett JL. et al, (2025), Neurology Neuroimmunology & Neuroinflammation, 12

Load More

1
2
3
4
5
6
7
...
»